Latest Sales Growth News

KMD Brands reports improving sales in direct-to-consumer channels for FY25’s first five months, offset by ongoing wholesale challenges and a forecasted dip in EBITDA.

Biome Australia Limited has expanded its distribution footprint to over 6,000 health retail and practitioner locations, marking a 20% increase in six months and advancing toward its Vision 27 target of 8,000 sites by FY27.

Cardiex Limited has commenced U.S. deliveries of its CONNEQT Pulse arterial health monitor alongside the launch of its companion CONNEQT App, marking a pivotal expansion into the American digital health market.

EZZ Life Science Holdings delivered a robust Q2 FY25 with a 16.6% increase in customer receipts and a 308% jump in operating cash flows, while gearing up for US market entry and expanding its global footprint.

The Calmer Co. International Limited has reported a remarkable surge in sales and cash receipts for the first half of FY25, exceeding the entire FY24 sales. Alongside a strategic CEO transition and factory upgrade, the company is sharpening its focus on profitable growth and cost control.

Firebrick Pharma has made notable progress expanding its Nasodine nasal spray in Singapore, securing major distribution and marketing agreements that set the stage for retail sales growth in 2025.

Aumake Limited has inked a two-year e-commerce collaboration with Sichuan Airlines, opening access to over 30 million passengers annually and initiating sales with a AU$281,361 purchase order of premium Australian alcohol.

PolyNovo Limited reports a robust 22.8% revenue increase in 1H FY25, driven by strong U.S. and international sales growth and progressing FDA approval efforts for its NovoSorb platform.

Immuron Limited reports a striking 70% quarter-on-quarter increase in Travelan® sales, driven by expanded pharmacy distribution in Australia and North America.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Advance ZincTek reports steady profit before tax for H1 FY25, driven by strong North American growth and significant cost savings following its Perth facility closure.